Duopharma Biotech Bhd's total inventories for the quarter that ended in Mar. 2026 was RM297.3 Mil. Duopharma Biotech Bhd's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was RM295.2 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Duopharma Biotech Bhd's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was RM-0.08.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Duopharma Biotech Bhd's Days Inventory for the
three
months ended in Mar. 2026 was 178.92.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Duopharma Biotech Bhd's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.51.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Duopharma Biotech Bhd's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 1.19.
Duopharma Biotech Bhd (XKLS:7148) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Duopharma Biotech Bhd's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Duopharma Biotech Bhd's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Duopharma Biotech Bhd Total Inventories Related Terms
Duopharma Biotech Bhd Total Inventories Historical Data
* Premium members only.
The historical data trend for Duopharma Biotech Bhd's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of RM297.3 Mil mean?
Duopharma Biotech Bhd (XKLS:7148) has a Total Inventories of RM297.3 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Duopharma Biotech Bhd and its competitors.
Is Duopharma Biotech Bhd's Total Inventories too high?
Duopharma Biotech Bhd's current Total Inventories is RM297.3 Mil. Overall, Duopharma Biotech Bhd has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Total Inventories compare to ZTS and UTHR?
Duopharma Biotech Bhd's Total Inventories of RM297.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Duopharma Biotech Bhd and its competitors. Duopharma Biotech Bhd's current Total Inventories is RM297.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.52, compared to a current price of RM1.20 — trading 21.1% below its estimated fair value. The current Total Inventories is RM297.3 Mil. Duopharma Biotech Bhd's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Total Inventories is RM297.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.20 is trading 21.1% below its estimated GF Value™ of RM1.52.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
Total Inventories: RM297.3 Mil
GF Value™: RM1.52 vs. price of RM1.20 (21.1% below fair value)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
82GF Score
Get the complete analysis for XKLS:7148
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
